Interleukin-17A and -17F genes polymorphisms in lung cancer

Cytokine

Volumn 66, Issue 1, 2014, Pages 23-29

  Kaabachi, Wajih ^a,b   Amor, Amira ben ^a,b   Kaabachi, Safa ^a,b   Rafrafi, Ahlem ^a,b   Tizaoui, Kalthoum ^a,b   Hamzaoui, Kamel ^a,b  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b ABDERRAHMAN MAMI HOSPITAL   (Tunisia)

Author keywords

Biological interaction; Interleukin 17; Lung cancer; Polymorphisms; Restriction fragment length polymorphism

Indexed keywords

BIOLOGICAL INTERACTION; INTERLEUKIN-17; LUNG CANCER; POLYMORPHISMS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTERLEUKIN-17; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING;

EID: 84893354734     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.12.012     Document Type: Article

References (49)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Pharoah P.D., Dunning A.M., Ponder B.A., Easton D.F. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004, 4:850-860.
3. Savas S., Liu G. Studying genetic variations in cancer prognosis (and risk): a primer for clinicians. Oncologist 2009, 14:657-666.
4. Broderick P., Wang Y., Vijayakrishnan J., Matakidou A., Spitz M.R., Eisen T., et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res 2009, 69:6633-6641.
5. Bai L., Yu H., Wang H., Su H., Zhao J., Zhao Y. Genetic single-nucleotide polymorphisms of inflammation-related factors associated with risk of lung cancer. Med Oncol 2013, 30:414.
6. Lim W.-Y., Chen Y., Ali S.M., Chuah K.L., Eng P., Leong S.S., et al. Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis 2011, 32:522-529.
7. Yi Q., Bin Z., Wang Yanyun, Ruiqi D., Wang Kana, Qianqian G., et al. Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin Dev Immunol 2012, 1-6.
8. Lihong W., Yongdong J., Youxue Z., Yuwen W., Sunhui H., Zhihua W., et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese han women with breast cancer. PLoS One 2012, 7:1-7.
9. Shibata T., Tahara T., Hirata I., Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol 2009, 70:547-551.
10. Zou W., Restifo N.P. TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010, 10:248-256.
11. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
12. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
13. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
14. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.-H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
15. Kawaguchi M., Adachi M., Oda N., Kokubu F., Huang S.-K. IL-17 cytokine family. J Allergy Clin Immunol 2004, 114:1265-1273.
16. Iwakura Y., Ishigame H., Saijo S., Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011, 34:149-162.
17. Reynolds J.M., Angkasekwinai P., Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 2010, 21:413-423.
18. Moseley T.A., Haudenschild D.R., Rose L., Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003, 14:155-174.
19. Nordang G.B., Viken M.K., Hollis-Moffatt J.E., Merriman T.R., Forre O.T., Helgetveit K., et al. Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. Rheumatol (Oxford) 2009, 48:367-370.
20. Arisawa T., Tahara T., Shibata T., Nagasaka M., Nakamura M., Kamiya Y., et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol 2008, 28:44-49.
21. Yan N., Yu Y.L., Yang J., Qin Q., Zhu Y.F., Wang X., et al. Association of interleukin-17A and -17F gene single-nucleotide polymorphisms with autoimmune thyroid diseases. Autoimmunity 2012, 45:533-539.
22. Navratilova Z., Gallo J., Mrazek F., Petrek M. Genetic variation in key molecules of the Th-17 immune response is not associated with risk for prosthetic joint infection in a Czech population. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012, 156:248-252.
23. Quan Y., Zhou B., Wang Y., Duan R., Wang K., Gao Q., et al. Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin Dev Immunol 2012, 2012:258293.
24. Ramsey C.D., Lazarus R., Camargo C.A., Weiss S.T., Celedon J.C. Polymorphisms in the interleukin 17F gene (IL17F) and asthma. Genes Immun 2005, 6:236-241.
25. Chen J., Deng Y., Zhao J., Luo Z., Peng W., Yang J., et al. The polymorphism of IL-17 G-152A was associated with childhood asthma and bacterial colonization of the hypopharynx in bronchiolitis. J Clin Immunol 2010, 30:539-545.
26. Miller S., Dykes D., Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
27. Paradowska-Gorycka A., Wojtecka-Lukasik E., Trefler J., Wojciechowska B., Lacki J., Maslinski S. Association between IL-17F Gene Polymorphisms and Susceptibility to and Severity of Rheumatoid Arthritis (RA). Scand J Immunol 2010, 72:134-141.
28. Barrett J.C., Fry B., Maller J., Daly M. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
29. Andersson T., Alfredsson L., Källberg H., Zdravkovic S., Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005, 20:575-579.
30. Knol M.J., VanderWeele T.J., Groenwold R.H., Klungel O.H., Rovers M.M., Grobbee D.E. Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol 2011, 26:433-438.
31. Kalilani L., Atashili J. Measuring additive interaction using odds ratios. Epidemiol Perspect Innov 2006, 3:5.
32. Wilke C.M., Kryczek I., Wei S., Zhao E., Wu K., Wang G., et al. Th17 cells in cancer: help or hindrance?. Carcinogenesis 2011, 32:643-649.
33. Liang S.C., Long A.J., Bennett F., Whitters M.J., Karim R., Collins M., et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 2007, 179:7791-7799.
34. Wright J.F., Guo Y., Quazi A., Luxenberg D.P., Bennett F., Ross J.F., et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem 2007, 282:13447-13455.
35. Pappu R., Ramirez-Carrozzi V., Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 2011, 134:8-16.
36. Angkasekwinai P, Dong C. TH17 cytokines: characteristics, regulation, and biological function. In: TH17 cells in health and disease. Springer; 2011. p. 27-40.
37. Chen X., Xie Q., Cheng X., Diao X., Cheng Y., Liu J., et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010, 101:2384-2390.
38. Li Q., Han Y., Fei G., Guo Z., Ren T., Liu Z. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 2012, 148:144-150.
39. Liu L., Ge D., Ma L., Mei J., Liu S., Zhang Q., et al. Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 2012, 7:1091-1100.
40. Reppert S., Boross I., Koslowski M., Tureci O., Koch S., Lehr H.A., et al. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun 2011, 20:2:600.
41. Wu X., Zeng Z., Chen B., Yu J., Xue L., Hao Y., et al. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer 2010, 127:86-92.
42. Arisawa T., Tahara T., Shiroeda H., Matsue Y., Minato T., Nomura T., et al. Genetic polymorphisms of IL17A and pri-microRNA-938, targeting IL17A 3'-UTR, influence susceptibility to gastric cancer. Hum Immunol 2012, 73:747-752.
43. Tahara T., Shibata T., Nakamura M., Yamashita H., Yoshioka D., Okubo M., et al. Association between IL-17A, -17F and MIF polymorphisms predispose to CpG island hyper-methylation in gastric cancer. Int J Mol Med 2010, 25:471-477.
44. Innocenti F., Owzar K., Cox N.L., Evans P., Kubo M., Zembutsu H., et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18:577-584.
45. Hizawa N., Kawaguchi M., Huang S.K., Nishimura M. Role of interleukin-17F in chronic inflammatory and allergic lung disease. Clin Exp Allergy 2006, 36:1109-1114.
46. Kawaguchi M., Takahashi D., Hizawa N., Suzuki S., Matsukura S., Kokubu F., et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 2006, 117:795-801.
47. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
48. Rafrafi A., Chahed B., Kaabachi S., Kaabachi W., Maalmi H., Hamzaoui K., et al. Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: a case control study. Hum Immunol 2013.
49. Espinoza J.L., Takami A., Nakata K., Onizuka M., Kawase T., Akiyama H., et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One 2011, 6:e26229.